Intelligence Briefing · ~4 min read
TEVA's ANDA219413 Submission Signals Potential Market Disruption
Not specified
Type
Strategic BriefingGenerated
Jul 23, 2026
Confidence
Moderate Confidence · 72%
Evidence
6 items
Sources
6
Key Takeaways
Leadership-ready summary — read in 4 minutes.
- Portfolio and strategy teams should assess the potential market entry of this generic product and its implications for pricing and competition. The strongest clinical anchor is Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillectomy Pain in Children (ClinicalTrials.gov), mechanism alignment (io ). In Not specified, 5 regulatory and 2 competitive items passed relevance filtering for TEVA PHARMACEUTICALS, INC.
- Monitor the FDA's review timeline and any subsequent approval announcements for ANDA219413.
- A timeline shift beyond mid-term would change urgency regarding competitive strategies.
Why It Matters
Strategic context for leadership and portfolio decision-making.
Portfolio and strategy teams should assess the potential market entry of this generic product and its implications for pricing and competition. The strongest clinical anchor is Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillectomy Pain in Children (ClinicalTrials.gov), mechanism alignment (io ). In Not specified, 5 regulatory and 2 competitive items passed relevance filtering for TEVA PHARMACEUTICALS, INC.
Supporting Evidence
Evidence-backed items from the Humanexa intelligence graph.
TEVA Pharmaceuticals submits ANDA219413 for FDA review
Not specified
Source: Regulatory Approval
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.